- Samsung Biologics has purchased land in Songdo, Incheon, to build a third campus supporting expanded CDMO capabilities.
- The company plans to invest about 7 trillion won in the site, projecting more than 10,000 jobs and economic impact through 2030.
Samsung Biologics has secured land for a new manufacturing campus in Songdo, Incheon, as the company prepares to expand its contract development and manufacturing (CDMO) portfolio beyond its established antibody operations. The land purchase agreement was signed with the Incheon Free Economic Zone Authority for a site within Songdo’s advanced industry cluster.
The industrial plot covers about 187,427 square metres, with the acquisition completed at a cost of 248.7 billion won after Samsung Biologics was named the preferred negotiation partner in June. The third campus will sit adjacent to the company’s existing facilities and is planned to integrate manufacturing, quality and technical functions across the sites.
The expansion will support new CDMO modalities, including cell and gene therapies, antibody-based vaccines and peptides. These efforts build on Samsung Biologics’ recent developments in mRNA, antibody drug conjugates and organoid technologies as it responds to demand for broader contract manufacturing capabilities.
The company expects the new campus layout to improve production efficiency, shorten project lead times for global clients and enhance regulatory responsiveness. Samsung Biologics plans to invest about 7 trillion won in the development, projecting more than 10,000 direct and indirect jobs and an estimated economic impact of 12 trillion won by 2030.
“The land agreement comes at a pivotal moment for the company following its spin-off into a pure-play CDMO entity. The expansion into new modalities will help accelerate the company’s progress toward becoming a leading global biopharmaceutical manufacturer.”
John Rim, CEO of Samsung Biologics
